Disseminated cryptococcal infection in a patient with glioblastoma multiforme on treatment with lomustine and bevacizumab

Lomustine and Bevacizumab in Progressive Glioblastoma.

BACKGROUND Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients...

Recurrent Glioblastoma Multiforme: Implication of Nonenhancing Lesions on Bevacizumab Treatment

Glioblastoma multiforme (GBM) is the most common primary brain tumors, accounting for 1520% of all intracranial tumors. It is one of the most lethal tumors of the central nervous system with a median survival from diagnosis on the order of 6 to 18 months. Despite aggressive resection and chemoradiation, the tumor always recurs. Magnetic Resonance (MR) imaging is an essential component in the di...

Bevacizumab for recurrent glioblastoma multiforme

Disseminated cryptococcal infection despite treatment for cryptococcal meningitis.

Case Reports (Dr R F Miller) Case 1 A 25 year old Caucasian heterosexual man was found to be HIV I antibody positive in July 1989, when he presented to another hospital with cryptococcal meningitis. At this time his CD4+ count was 190 (normal range = 350-2,200)/mm3. Investigations showed normal urea and electrolyte levels and liver function tests; CT of the head was normal. Blood and urine cult...

Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

INTRODUCTION Glioblastoma multiforme (GBM) is the most common high grade primary brain tumor in adults. Despite significant advances in treatment, the prognosis remains poor. Bevacizumab (BVZ) and irinotecan (CPT-11) are currently being investigated in the treatment of GBM patients. Although treatment with BVZ and irinotecan provides impressive response rates (RR), it is still uncertain if this...